Avalo Therapeutics's total assets for Q3 2024 were $98.45M, a decrease of -9.10% from the previous quarter. AVTX total liabilities were $75.72M for the fiscal quarter, a -31.45% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.